MedTrace Logo

Osteoporosis Prevention With Low Dose Alendronate

NCT00463268 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 83

Last updated 2013-05-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of the intermittent administration of alendronate in a low dose, 70 mg once every two week, as osteoporosis prevention for menopausal, osteopenic patients, who don't want or can't receive an oestrogenic substitution treatment.

Conditions

  • Osteopenia

Interventions

DRUG

alendronate

alendronate 70 mg every 2 weeks

DIETARY_SUPPLEMENT

Calcium/Vitamin D

Calcium 500 mg and vitamin D supplementation according to serum level

DRUG

placebo

identical placebo every 2 weeks

Sponsors & Collaborators

  • University Hospital of Mont-Godinne

    lead OTHER

Principal Investigators

  • Yves R Boutsen, MD

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00463268 on ClinicalTrials.gov